BIOSINO BIO-TEC (08247) has unveiled significant board changes following its extraordinary general meeting. Effective immediately after the meeting's conclusion, Wu Lebin departed from his director position upon shareholder approval of his removal. Subsequent to this departure, the board confirmed that as of July 15, 2025: (i) Wu has relinquished his roles as nomination committee member and authorized representative; and (ii) Chen Zhengyong, executive director and board chairman, has assumed the position of authorized representative.
Concurrently, Lu Qi's resignation as independent non-executive director took effect at the meeting's close, coinciding with shareholders' endorsement of Fan Xiaoliang's appointment to the same role. Further transitions announced effective July 15 include: (i) Lu stepping down as chairman of both audit and nomination committees while exiting the remuneration committee; and (ii) Chen Zhengyong taking the helm as nomination committee chairman.
The shareholders' meeting also ratified the appointments of Dr. Shen Sheng as non-executive director and Fan Xiaoliang as independent non-executive director, both effective July 15, 2025. In a complementary move, the board appointed Fan as chairman of the audit committee effective the same date, completing this comprehensive leadership restructuring.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.